Werewolf Therapeutics (HOWL) vs Tonix Pharmaceuticals (TNXP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Werewolf Therapeutics (HOWL) has outperformed Tonix Pharmaceuticals (TNXP) over the past year, gaining 8.4% versus a loss of 85.2%. Over five years, HOWL leads with a -93.7% price change compared with -100.0% for TNXP. Tonix Pharmaceuticals is the larger company by market cap ($46.2 million vs $46.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HOWL | TNXP |
|---|---|---|
| Share price | $0.9466 | $2.38 |
| Market cap | $46.00M | $46.25M |
| 1-day change | -3.97% | -6.67% |
| YTD return | +49.31% | -84.76% |
| 1-year return | +8.43% | -85.22% |
| 5-year return | -93.68% | -100.00% |
| EPS (TTM) | $-0.58 | $-12.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $13.11M |
| Revenue growth (YoY) | — | +29.85% |
| Net income (latest FY) | $-60.82M | $-124.02M |
| Gross margin | — | 49.34% |
| Operating margin | — | -959.05% |
| Net margin | — | -946.22% |
| 52-week high | $1.20 | $20.56 |
| 52-week low | $0.27 | $2.30 |
| Distance from 52-week high | -21.12% | -88.42% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +639.49% | +1769.75% |
| Average volume | 1.08M | 838.83K |
| Shares outstanding | 48.60M | 19.43M |
| Employees | 39 | 142 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HOWL has outperformed TNXP by 93.6 percentage points over the past year.
About Werewolf Therapeutics
HOWL stock →Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees
About Tonix Pharmaceuticals
TNXP stock →Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia.
Health Care · Biotechnology: Pharmaceutical Preparations · 142 employees
HOWL vs TNXP FAQ
Which is bigger, Werewolf Therapeutics or Tonix Pharmaceuticals?
Tonix Pharmaceuticals (TNXP) is larger, with a market capitalization of $46.25M compared with $46.00M for Werewolf Therapeutics (HOWL).
Which stock has performed better over the past year, HOWL or TNXP?
HOWL returned +8.43% over the past 12 months, compared with -85.22% for TNXP (price return, excluding dividends). Past performance does not predict future results.
Are Werewolf Therapeutics and Tonix Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.